ArticleFrontiers in medicine2026
Marked improvement of isolated acrodermatitis continua of hallopeau with upadacitinib: a case report and literature review.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acrodermatitis continua of Hallopeau (ACH) is a rare and chronic variant of pustular psoriasis characterized by sterile pustules, periungual inflammation, and progressive nail destruction. Due to its rarity and overlapping clinical features with other nail disorders, ACH is frequently underrecognized and remains difficult to treat, with no standardized therapeutic guidelines. Here, we report a case of long-standing, isolated ACH showing marked improvement after treatment with the selective Janus kinase 1 (JAK1) inhibitor upadacitinib. A 54-year-old man presented with a 13-year history of recurrent periungual erythema, sterile pustules, and progressive nail dystrophy affecting multiple digits. The disease was refractory to topical corticosteroids, systemic antibiotics, acitretin, and 1 year of secukinumab therapy. Following initiation of upadacitinib 15 mg daily, rapid clinical improvement was observed within 4 weeks, with reduction of subungual pustules and periungual inflammation. Nail involvement subsequently improved gradually, accompanied by nail regrowth and a decrease in the modified Nail Psoriasis Severity Index score from 66 at baseline to 16 at week 24 and 13 at month 9. No adverse or unanticipated events were observed during follow-up. This case highlights the potential role of JAK1 inhibition as an effective therapeutic strategy for refractory ACH and supports further investigation into JAK-targeted therapies in pustular psoriasis spectrum disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.